Equities Analysts Issue Forecasts for VRTX FY2027 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Stock analysts at Erste Group Bank issued their FY2027 earnings estimates for Vertex Pharmaceuticals in a research report issued on Wednesday, February 18th. Erste Group Bank analyst H. Engel forecasts that the pharmaceutical company will post earnings of $19.31 per share for the year. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Several other research firms also recently commented on VRTX. UBS Group increased their target price on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Stifel Nicolaus increased their price objective on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a report on Friday, February 13th. Wells Fargo & Company raised their price objective on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $590.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Finally, Royal Bank Of Canada lowered their price target on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a report on Friday, February 13th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $542.00.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $476.90 on Monday. The stock’s 50 day moving average price is $463.26 and its 200 day moving average price is $428.83. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $519.68. The company has a market capitalization of $121.15 billion, a P/E ratio of 31.11 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same period last year, the business earned $3.98 EPS. The company’s quarterly revenue was up 9.5% on a year-over-year basis.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Earned Wealth Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 3.3% during the 4th quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company’s stock valued at $295,000 after acquiring an additional 21 shares in the last quarter. Confluence Wealth Services Inc. lifted its stake in Vertex Pharmaceuticals by 4.0% during the fourth quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock worth $247,000 after purchasing an additional 21 shares during the period. Williams Jones Wealth Management LLC. boosted its holdings in Vertex Pharmaceuticals by 1.9% during the fourth quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock valued at $524,000 after purchasing an additional 21 shares in the last quarter. Childress Capital Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 3.1% in the 4th quarter. Childress Capital Advisors LLC now owns 730 shares of the pharmaceutical company’s stock valued at $331,000 after purchasing an additional 22 shares during the period. Finally, Kovack Advisors Inc. raised its holdings in shares of Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock worth $570,000 after buying an additional 24 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total value of $6,384,000.00. Following the completion of the transaction, the executive vice president directly owned 37,725 shares in the company, valued at approximately $17,202,600. This represents a 27.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Ourania Tatsis sold 4,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the completion of the transaction, the executive vice president directly owned 42,293 shares of the company’s stock, valued at approximately $20,088,752.07. This trade represents a 9.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 100,852 shares of company stock worth $45,787,299. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.